s6y

TFA Therapeutics, Inc.

Ticker
RAJAF
CIK
1885680
Industry
Medicinal Chemicals & Botanical Products
Formerly
Cordyceps Sunshine Biotech Holdings Co., Ltd.

Financials 4

  1. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2025
  2. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2024
  3. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2023
  4. NT 20-F Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F for period ending Dec 31, 2022

Prospectus 6

  1. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  2. DRSLTR Correspondence Related to Draft Registration Statement
  3. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  4. DRSLTR Correspondence Related to Draft Registration Statement
  5. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  6. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Other 28

  1. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  2. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  3. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  4. 20-F Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
  5. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  6. 20-F/A Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
  7. 20-F Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
  8. 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
  9. UPLOAD Letter (PDF)
  10. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

All 28 other filings